Eli Lilly
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. The Сompany also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its prodcuts, include Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include: Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.
Key People/Management at Eli Lilly
David Ricks
Susan Mahony
Jeffrey Simmons
Alfonso Zulueta
Stephen Fry
Melissa Barnes
Eli Lilly Office Locations
Eli Lilly Financials and Metrics
Eli Lilly Financials
| USD | |
|---|---|
Revenue (FY, 2016) | 21.2 b |
Revenue growth (FY, 2015 - FY, 2016), % | 6.3% |
Gross profit (FY, 2016) | 15.6 b |
Gross profit margin (FY, 2016), % | 73.4% |
Net income (FY, 2016) | 2.7 b |
Market capitalization (25-Apr-2018) | 85.4 b |
Cash (31-Dec-2016) | 4.6 b |
EV | 89.1 b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 23.1 b | 19.6 b | 20 b | 21.2 b |
Revenue growth, % | (15%) | 2% | 6% | |
Cost of goods sold | 4.9 b | 4.9 b | 5 b | 5.7 b |
Gross profit | 18.2 b | 14.7 b | 14.9 b | 15.6 b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 3.8 b | 3.9 b | 3.7 b | 4.6 b |
Accounts Receivable | 588.4 m | 566.7 m | 558.6 m | 736.9 m |
Inventories | 2.9 b | 2.7 b | 3.4 b | 3.6 b |
Current Assets | 13.1 b | 12.2 b | 12.6 b | 15.1 b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 4.7 b | 2.4 b | 2.4 b | 2.7 b |
Cash From Operating Activities | 5.7 b | 4.4 b | 2.8 b | 4.9 b |
Purchases of PP&E | (1 b) | (1.2 b) | (1.1 b) | (1 b) |
Cash From Investing Activities | (2.1 b) | (3.9 b) | 26.8 m | (3.1 b) |
| USD | Y, 2016 |
|---|---|
EV/CFO | 18.4 x |
Revenue/Employee | 511.3 k |
Debt/Equity | 0.6 x |
Debt/Assets | 0.2 x |
Financial Leverage | 2.8 x |
Eli Lilly Operating Metrics
| FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | |
|---|---|---|---|---|
Phase III Trials Products | 8 | 7 | 17 | 19 |
Projects in R&D Pipeline | 57 | 57 | 65 | 66 |
Eli Lilly Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| CoLucid Pharmaceuticals | January 18, 2017 | $960 m |
| Novartis Animal Health | April 22, 2014 | $5.40 b |
| Avid Radiopharmaceuticals | November 08, 2010 | $800 m |
| Alnara Pharmaceuticals | July 02, 2010 | $280 m |
| Imclone Systems | October 06, 2008 | $6.50 b |
